OKYO - Dry Eye Disease Affects Around 50M Americans OKYO Pharma's Candidate Shows Safety In Mid-Stage Study | Benzinga
OKYO Pharma Limited (NASDAQ: OKYO) announced that its first drug candidate, OK-101, presently in a 240-patient phase 2 trial in patients with dry eye disease (DED) is currently showing a positive safety profile in the ongoing study.
Patients continue in the study, and double-blind procedures are still in effect until all patients complete the 12-week dosing duration.
OKYO will continue ...